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Summary
Aim We aimed to investigate the efficacy of interferon
and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV)
and ritonavir boosted paritaprevir/ombitasvir with
or without dasabuvir (2D/3D) regimens in a real-life
cohort of human immunodeficiency virus/hepatitis
C virus (HIV/HCV) coinfected patients. The study
focused on efficacy, need for changes in antiretroviral
therapy (ART) due to drug-drug interaction (DDI),
and treatment-associated changes in liver stiffness.
Methods In this study 36 patients (n = 21 SOF/LDV
and n = 15 2D/3D) were retrospectively analyzed.
Depending on the genotype the following treatment
regimens were used: HCV genotype (GT)-1: either
SOF/LDV or 3D, no patient with HCV-GT2 was in-
cluded, HCV-GT3: SOF/LDV, HCV-GT4: 2D.
Results Approximately one third (35.3%) of patients
were treatment-experienced and 13.9% had cirrhosis.
Antiretroviral therapy had to be changed in 38.1%
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of SOF/LDV and 60% of 2D/3D patients prior to
anti-HCV treatment due to expected DDIs. We ob-
served sustained virologic response (SVR) rates of
100% in patients treated with SOF/LDV (19/19) and
2D/3D (14/14). One 2D/3D patient was lost to follow-
up, while two SOF/LDV patients died during ther-
apy from non-treatment-related causes. They were
excluded from the analysis. Between baseline and fol-
low-up liver stiffness decreased from 11.4 to 8.3 kPa
(p = 0.008) and from 8.1 to 5.7 kPa (p = 0.001) in
SOF/LDV and 2D/3D patients, respectively.
Conclusions We confirmed the excellent HCV erad-
ication rates >95% in a real-life cohort of HIV/HCV
coinfected patients treated with SOF/LDV and 2D/3D.
We observed no HCV relapse or breakthrough. More
patients treated with 2D/3D required a change in ART
than patients treated with SOF/LDV. Additionally, HCV
eradication led to a rapid decline in liver stiffness.
Keywords HIV · Hepatitis C virus · Sofosbuvir · Ledi-
pasvir · 3D
Introduction
Chronic hepatitis C virus (HCV) infections are esti-
mated to affect 0.3% of the overall population in Aus-
tria; however, only one third of patients are aware
of their infection [1]. According to the Joint United
Nations Programme on HIV/AIDS (UNAIDS) approx-
imately 9000 people in Austria are living with human
immunodeficiency virus (HIV) [2]. Of those approxi-
mately 20% are coinfected with HCV [3]. Liver-related
mortality, mainly due to viral hepatitis, remains a ma-
jor cause of death amongst HIV-positive individuals
[4]. When compared with HCV mono-infected pa-
tients, HIV/HCV coinfected patients progress faster to
cirrhosis [5] and show increased liver-related mortal-
ity [6, 7]. Since eradication of HCV improves overall
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survival among HIV/HCV coinfected patients [8], the
European Association for the Study of the Liver (EASL)
recommends prioritizing treatment of HCV in patients
who are coinfected with HIV [9].
In 2008 there were an estimated 38,000 (range
8000–60,000) individuals with anti-HCV antibodies
(anti-HCV prevalence rate of 0.5%; (0.1–0.7%)) [2, 26].
With a viremic rate of 73.9%, there were approxi-
mately 28,000 (range 6000–44,000) viremic individ-
uals, corresponding to a viremic prevalence rate of
0.3% (0.1–0.5%).
In the era of pegylated interferon (IFN) and rib-
avirin (RBV), the majority of HIV/HCV coinfected pa-
tients remained untreated for HCV [10]. Patients with
an urgent need for treatment due to established cir-
rhosis as well as those with psychiatric comorbidities
were often not eligible for IFN-based therapy. Further-
more, even eligible patients refused anti-HCV therapy
since adverse events (AEs) were common while the
chance of cure was suboptimal [10–12].
Triple therapy with IFN/RBV plus one of the first
generation direct acting antivirals (DAA) boceprevir
[13] or telaprevir [14] achieved higher rates of sus-
tained virologic response (SVR); however, their use
was limited to HCV genotype (HCV-GT) 1 and treat-
ment acceptance remained low due to contraindica-
tions, significant impairments of health-related qual-
ity of life during treatment [15] and patient refusal
[16].
With the approval of second generation DAAs by
the European Medicines Agency a new era of HCV
therapy has started. Currently, IFN-free DAA com-
binations are only reimbursed by Austrian health
insurance if a patient has significant liver fibrosis
(METAVIR score ≥F2 or liver stiffness ≥7.0 kPa). Avail-
able and reimbursed second generation DAA regi-
mens include sofosbuvir/ledipasvir (SOF/LDV) [17]
and ritonavir boosted paritaprevir/ombitasvir with
(3D) or without (2D) dasabuvir [18] which demon-
strated excellent cure rates in clinical trials. In the
ION-4 trial [17] SOF/LDV achieved an overall SVR rate
of 96% in HIV/HCV coinfected patients with HCV-
GT1 and HCV-GT4 treated for 12 weeks. In the ELEC-
TRON-2 [19] trial SOF/LDV for 12 weeks achieved
a SVR rate of only 64% in HCV-GT3 patients, while
those who additionally received RBV had a SVR rate
of 100%. In the ION-4 [17] trial SOF/LDV was well-
tolerated with no discontinuation due to treatment-
related AE.
In the TURQUOISE-1 [18] trial, 3D in combi-
nation with RBV achieved an SVR rate of 94% in
HIV/HCV coinfected patients with HCV-GT1 treated
for 12 weeks. The AE were rare and no patient dis-
continued treatment. The PEARL-1 [20] study inves-
tigated the use of 2D for HCV-GT4 and achieved SVR
rates of 91% in non-cirrhotic, treatment-naïve HCV
monoinfected patients; however, due to strict inclu-
sion and exclusion criteria the majority of coinfected
patients would not have been able to participate in the
ION-4 and TURQUOISE-1 trials [21]. In these trials,
patients were commonly excluded due to restrictions
to specific antiretroviral therapies, active drug use,
detectable HIV-RNA or due to low CD4 cell counts.
Thus, it is uncertain whether these promising results
can be extrapolated to real-life patients. Due to the
addition of the ritonavir boosted protease-inhibitor
paritaprevir, 2D/3D carries a substantial potential for
drug-drug interactions (DDI) [22]. Although SOF/LDV
moderately increases tenofovir disoproxil fumarate
(TDF) levels similar to those seen when combining
TDF with a ritonavir boosted HIV protease inhibitor
(PI) [22], no dose adjustments or changes in antiretro-
viral therapy (ART) are necessary. In contrast, the use
of 2D/3D in combination with HIV PI or non-nucle-
oside reverse transcriptase inhibitors (NNRTI) is not
recommended due to DDI [23].
Liver stiffness measured by transient elastography
is a surrogate marker of liver fibrosis [24] and portal
hypertension [25] and predicts hepatic decompensa-
tion in HIV/HCV coinfected patients [26]. Interest-
ingly, recent studies revealed that both IFN-based [27]
and IFN-free therapies [28] improved liver stiffness in
HIV/HCV coinfected patients, suggesting liver fibrosis
regression and a reduction in portal pressure [29].
The real-life efficacy of SOF/LDV and 2D/3D has yet
to be demonstrated in HIV/HCV coinfected patients
[21]. Thus, we investigated the efficacy of IFN and
RBV-free SOF/LDV and 2D/3D regimens in a real-life
cohort of HIV/HCV coinfected patients. Moreover, we
assessed the need for changes in ART due to DDI as
well as the course of liver stiffness.
Patients, materials and methods
Study population
All HIV/HCV coinfected patients treated at the Med-
ical University of Vienna with either SOF/LDV or
2D/3D who completed the SVR visit by July 2016 were
retrospectively analyzed. Based on these criteria 36
patients were included: SOF/LDV n = 21 and 2D/3D
n = 15.
Assessed parameters
Epidemiological characteristics and HIV as well as
HCV infection parameters were collected from pa-
tient medical history. HCV-GT was determined using
the VERSANT HCV Genotype 2.0 Assay Line Probe
Assay (LiPA) (Siemens Healthcare Diagnostics, Tarry-
town, NY), while HCV-RNA was assessed using the
Abbott RealTime HCV assay (Abbott Molecular, Des
Plaines, IL) with a lower limit of quantification (LLQ)
of 12 IU × ml–1.
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Table 1 Patient characteristics
Overall SOF/LDV 2D/3D p-value
Age (years) 43.7 ± 2.8 45 ± 2.4 41.9 ± 3.2 0.419
Sex
Male 26 (72.2%) 16 (76.2%) 10 (66.7%) 0.709
Female 10 (27.8%) 5 (23.8%) 5 (33.3%)
BMI 24.4 ± 1.4 23.8 ± 1.4 25.3 ± 1.4 0.426
History of alcohol abuse 7 (19.4%) 4 (19%) 3 (20.0%) 1
HCV infection parameters
Baseline HCV-RNA (log IU × ml–1) 6.12 ± 0.2 6.22 ± 0.16 5.98 ± 0.23 0.392
HCV genotype
HCV-GT1 25 (69.4%) 13 (61.9%) 12 (80.0%) n. a.
HCV-GT2 0 0 0
HCV-GT3 8 (22.2%) 8 (38.1%) 0
HCV-GT4 3 (8.3%) 0 3 (20.0%)
Transmission
IVDA 22 (61.1%) 13 (61.9%) 9 (60%) n. a.
MSM 7 (19.4%) 4 (19.0%) 3 (20%)
Heterosexual contact 4 (11.1%) 3 (14.3%) 1 (6.7%)
Other 1 (2.8%) 0 1 (6.7%)
Unknown 2 (5.6%) 1 (4.8%) 1 (6.7%)
Previous HCV treatment 12 (35.3%) 6 (28.6%) 7 (46.7%) 0.462
HIV infection parameters
Antiretroviral therapy 35 (97.2%) 20 (95.2%) 15 (100%) 1
HIV-RNA suppression at baseline 27 (84.4%) 15 (75%) 12 (100%) 0.130
CD4+ T lymphocyte nadir (cells/μL) 300 ± 62 293 ± 49 311 ± 79 0.879
CD4+ T lymphocytes (cells/μl) 654 ± 99 617 ± 85 699 ± 112 0.664
Liver stiffness ≥7.1 kPa 16 (44.4%) 8 (38.1%) 8 (53.3%) 0.310
Liver stiffness ≥9.5 kPa 5 (13.9%) 3 (14.3%) 2 (13.3%) 1
Liver stiffness ≥12.5 kPa 5 (13.9%) 4 (19.0%) 1 (6.7%) 0.376
Portal hypertension ≥6mmHg 6 (16.6%) 4 (19.0%) 2 (13.3%) 1
Clinically significant portal hyperten-
sion ≥10mmHg
3 (8.3%) 3 (14.3%) 0 0.250
AST (IU/mL) 72.03 ± 14.23 85.38 ± 16.62 53.33 ± 7.86 0.101
ALT (IU/mL) 108.33 ± 33.24 140.33 ± 40.61 63.53 ± 11.32 0.092
GGT (IU/mL) 148.61 ± 37.15 155.67 ± 41.07 138.73 ± 30.67 0.745
Creatinine (mg/dL) 1.22 ± 0.57 0.83 ± 0.05 1.79 ± 0.89 0.238
Bilirubin (mg/dL) 0.77 ± 0.16 0.83 ± 0.18 0.69 ± 0.12 0.523
Albumin (g/dL) 43.57 ± 0.93 42.95 ± 1.02 44.44 ± 0.74 0.251
Prothrombin ratio (%) 94.06 ± 4.25 94.25 ± 3.46 93.79 ± 5.18 0.940
AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutaryltransaminase, GT genotype, SOF sofosbuvir, LDV ledipasvir, 2D ritanovir
boosted ombitasvir/paritaprevir, 3D ritonavir boosted ombitasvir/paritaprevir/dasabuvir, BMI body mass index; HCV hepatitis C virus, HIV human immunodefi-
ciency virus, IVDA intravenous drug abuse, MSM men who have sex with men, GT genotype
HIV therapy
Prior to HCV treatment initiation, ART was changed
to two nucleoside reverse transcriptase inhibitors
(NRTIs) combined with an integrase inhibitor (II) in
the case of suspected DDIs, tolerance reasons, or
for HIV treatment simplification (reduction of pill
burden). HIV-RNA was assessed using the Roche
COBAS® TqaMan HIV-1 Test, v2.0 (Roche, Vienna,
Austria) with a LLQ of 20 copies × ml–1.
HCV therapy
The decision on the therapy regimen was made
based on HCV-GT and reimbursement by the Aus-
trian health insurance. The following regimens were
used: HCV-GT1: either SOF/LDV or 3D, no patient
with HCV-GT2 was included, HCV-GT3: SOF/LDV,
HCV-GT4: 2D. A total of 21 patients were treated
with SOF/LDV (Harvoni® 400/90mg, Gilead, Vienna,
Austria) and 15 patients were treated with ombitasvir/
paritaprevir/ritonavir (Viekirax® 12.5mg/75mg/50mg,
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Table 2 Antiretroviral therapy
Treatment regimen SOF/LDV 2D/3D
3TC 6 (28.6%) 7 (46.6%)
ABC 5 (23.8%) 7 (46.6%)
TDF 15 (71.4%) 8 (53.3%)
FTC 14 (66.7%) 8 (53.3%)
ATZ 1 (4.8%) 1 (6.7%)
DRV 2 (9.5%) 0
FPV 1 (4.8%) 0
RTV 4 (19.0%) 1 (6.7%)
RPV 1 (4.8%) 1 (6.7%)
ETR 2 (9.5%) 0
RAL 5 (23.8%) 3 (20%)
DTG 10 (47.6%) 10 (66.7%)
3TC lamivudine, ABC abacavir, TDF tenofovir disoproxil fumarate, FTC emtricitabine, ATZ atazanavir, DRV darunavir, FPV fosamprenavir, RTV ritonavir,
RPV rilpivirine, ETR etravirine, RAL raltegravir, DTG dolutegravir
Abbvie, Vienna, Austria) two tablets once daily. In
the case of HCV-GT1 infection, dasabuvir (Exviera®
250mg, Abbvie, Vienna, Austria) twice daily was
added. Treatment duration was 12 weeks, except for
patients with cirrhosis or HCV-GT3 in whom the treat-
ment duration was extended to 24 weeks. In HCV-GT3
patients with excellent virologic response treatment
duration was shortened to 16 or 20 weeks; however,
in some patients, treatment prolongation was denied
by the Austrian health insurance. Sustained virologic
response (SVR) was defined as a negative PCR result
12 weeks after cessation of treatment.
Liver stiffness measurement
Liver stiffness was measured at baseline and follow-
up 12 weeks after cessation of treatment via transient
elastography (Fibroscan, Echosens, Paris, France), as
previously described [24].
Statistics
Analyses were performed using IBM SPSS Statistics 23
(SPSS, IBM, Armonk, NY) and GraphPad Prism 7
(GraphPad Software, La Jolla, CA). Continuous vari-
ables were reported as mean ± standard error of the
mean, whereas categorical variables were reported as
number and proportion of patients with the certain
characteristic. Student’s t-test was used for com-
parisons of continuous variables. Comparisons of
categorical variables were performed using Fisher’s
exact test. Paired t-test was used for comparing base-
line and follow-up liver stiffness. A p-value ≤0.05 was
denoted statistically significant.
Ethics
This study was conducted in accordance with the
Declaration of Helsinki and approved by the local




A full list of patient characteristic is given in (Table 1).
The majority of patients were male (72.2%), the
main route of transmission was intravenous drug use
(61.1%) and HCV-GT1 was most common (69.4%).
Approximately one third (35.3%) of patients was treat-
ment-experienced. The proportion of treatment-ex-
perienced patients was not significantly higher in the
2D/3D group (46.7% vs 28.6%; p = 0.462). Except for
one patient, all patients (97.2%) were on ART prior
to and during treatment and in the majority of cases
(84.4%) HIV-RNA was suppressed (<50 copies/ml).
The distribution of fibrosis stages assessed by tran-
sient elastography was as follows when using cut-offs
proposed by Castera et al. [30]: F2 (7.1–9.4 kPa): n =
16 (44.4%), F3 (9.5–12.4 kPa): n = 5 (13.9%), and F4
(≥12.5 kPa): n = 5 (13.9%). Of the patients 6 (16.6%)
had portal hypertension as indicated by a hepatic
venous pressure gradient ≥6mmHg.
No statistically significant differences in patient
characteristics were observed when comparing SOF/
LDV and 2D/3D patients. The antiretroviral therapy
used during SOF/LDV or 2D/3D treatment is shown
in Table 2.
The majority of patients in both groups received
nucleoside reverse transcriptase inhibitors (NRTI)
combined with an integrase inhibitor (II). In 8 (38.1%)
SOF/LDV (Fig. 1a) and 9 (60%) 2D/3D patients
(Fig. 1b) ART had to be switched to a regimen con-
taining 2 NRTI and an II prior to HCV therapy. In
one patient, without HIV therapy at baseline who had
a preserved CD4+ T-cell count, ART was initiated at
week 12 of anti-HCV therapy.
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Fig. 1 Antiretroviral therapy prior to and during anti-HCV ther-
apy. a, b Percentage of patients without ART during ther-
apy, or with same ART as before anti-HCV treatment, or with
switched ART to a compatible ART regimen prior to therapy,
indicated separately for SOF/LDV and 2D/3D. c, d Numbers
and proportion of patients using different classes of ART drugs
in their ART regimens during anti-HCV therapy, indicated for
SOF/LDV and 2D/3D, respectively. ART antiretroviral therapy,
SOFsofosbuvir,LDV ledipasvir,2D ritonavirboostedombitasvir/
paritaprevir, 3D ritonavir boosted ombitasvir/paritaprevir/
dasabuvir, NRTI nucleoside reverse transcriptase inhibitor,
NNRTI non-nucleoside reverse transcriptase inhibitor, PI pro-
tease inhibitor, II integrase inhibitor
In the SOF/LDV group, the NRTI backbone was
combined with NNRTI in n = 3 (14.3%), PIs in n = 4
(19.0%), and with IIs in n = 15 (71.4%) patients
(Fig. 1c). In the 2D/3D group, IIs were more common
with n = 13 (86.6%), while only n = 1 (6.7%) patient
received NNRTIs and PIs, respectively (Fig. 1d).
TDF (SOF/LDV: 15 [71.4%], 2D/3D: 8 [53.3%])
and emtricitabine (SOF/LDV: 14 [66.7%], 2D/3D: 8
[53.3%]) were the most commonly used NRTIs, while
dolutegravir (SOF/LDV: 10 [47.6%], 2D/3D: 10 [66.7%])
was the most commonly used II.
The virological response to SOF/LDV and 2D/3D
regimens is depicted in Fig. 2.
The viral kinetics during SOF/LDV and 2D/3D
treatment was similar. After 4 weeks of treatment 2
out of 18 (11%) and 9 out of 18 (50%) patients treated
with SOF/LDV had undetectable HCV-RNA and HCV-
RNA below the lower limit of quantification (LLQ)
respectively, compared with 4/14 (28.6%) and 3/14
(21.4%). treated with 2D/3D. At treatment week 8
the same applied to 7/19 (36.8%) and 10/19 (52.6%)
patients treated with SOF/LDV and 7 (46.7%) and
5/15 (33.3%) patients treated with 2D/3D (Fig. 2a).
Treatment was prolonged for up to 24 weeks in 7
(33.3%) and 2 (13.3%) patients treated with SOF/LDV
and 2D/3D, respectively.
In the SOF/LDV group 16 out of 19 (84.2%) pa-
tients had undetectable HCV-RNA at the end of treat-
ment and 19 out of 19 (100% [95% CI: 80.2–100%]) pa-
tients achieved SVR. We observed no relapse or break-
through, but two patients died during therapy from
non-treatment-related causes and were excluded from
the analysis. In contrast in the 2D/3D group 11 out
of 15 (73.3%) patients had an end of treatment re-
sponse but all 2D/3D patients (14 out of 14, 100%
[95% CI: 74.9–100%]) went on to achieve SVR. One
patient treated with 2D/3D was lost to follow-up and
excluded from the analysis (Fig. 2b).
Safety
The SOF/LDV and 2D/3D regimens were generally
well-tolerated; however, one patient treated with
SOF/LDV discontinued treatment at week 12 due to
worsening of a pre-existing cardiomyopathy. Further-
more, two patients died from non-treatment-related
causes: one due to a pre-existing CNS lymphoma,
while the other death was AIDS-related. No patients
treated with 2D/3D discontinued antiviral therapy
prior to week 12 of 2D/3D.
Change in liver stiffness
Paired liver stiffness measurements were available in
19 (90.5%) and 13 (86.7%) of SOF/LDV and 2D/3D
patients, respectively. Between baseline and follow-
up, liver stiffness decreased from 11.4 to 8.3 kPa (p =
0.008) and from 8.1 to 5.7 kPa (p = 0.001) in SOF/LDV
and 2D/3D patients, respectively (Fig. 2c). Interest-
ingly a small group of 5 (26.3%) and 2 (15.4%) patients
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Fig. 2 Treatment response. aViral kineticsofHCV-RNAat
baselineandduringtherapy(weeks2to12)areshownasmean±
standarderror of themeanat the respective timepoints for
SOF/LDVand2D/3D, respectively. bProportionofpatientswith
endof treatment negativity andSVRafter cessationof therapy
are shown for SOF/LDVand2D/3D, respectively.cChanges
in liver stiffness frombaseline to follow-up (evaluatedatSVR)




ment,SVR sustainedvirologic response,TND target notde-
tectable
showed increases in liver stiffness after SOF/LDV and
2D/3D treatment, respectively.
HIV suppression during therapy
Low HIV viremia (either HIV-RNA <LLQ or ≥LLQ)
was common during anti-HCV treatment. In the
SOF/LDV group, 9 (45%) and 5 (25%) patients showed
detectable HIV-RNA <LLQ and HIV-RNA ≥LLQ, re-
spectively (Fig. 3a). The patient without ART at
baseline was excluded from this analysis. In the
2D/3D group, HIV-RNA ≥LLQ was less common with
1 (6.7%) and 9 (60%) showing detectable HIV-RNA
<LLQ (Fig. 3b); however, the trend toward a higher
rate of HIV-RNA ≥LLQ in the SOF/LDV group was
not statistically significant (p = 0.207). Prior to treat-
ment 7 (35%) and 3 (15%) patients showed detectable
HIV-RNA <LLQ and HIV-RNA ≥LLQ in the SOF/LDV
group, respectively. In the 2D/3D group 5 (33.3%) and
1 (6.7%) patients showed detectable HIV-RNA <LLQ
and HIV-RNA ≥LLQ prior to treatment, respectively.
The difference in viremia prior to and during DAA
treatment was not statistically significant between the
SOF/LDV and the 2D/3D groups.
Discussion
Our study aimed to investigate the real-life efficacy of
SOF/LDV and the 2D/3D regimen in a cohort of thor-
oughly documented HIV/HCV coinfected patients.
Due to the reimbursement requirements of the Aus-
trian health insurance, nearly all patients had to have
at least liver fibrosis ≥F2. Nevertheless, compared
with other studies [31], cirrhosis was less common
as most patients with an urgent need for therapy
have been treated as soon as sofosbuvir/daclatasvir
became available [28].
The ION-4 [17] and the TURQUOISE-1 [18] trial
assessed the efficacy of SOF/LDV and 3D in HIV/HCV
coinfected patients and demonstrated remarkable
SVR rates of ≥95%; however, their generalizability
to the real world has recently been questioned [21];
therefore, we investigated whether SVR rates ≥95%
were achievable in a real-world setting. In analogy
to other reports [31], our study confirms these num-
bers; however, another recent study by Lakshmi et
al. reported a substantially lower cure rate of only
83.3% in their HIV/HCV coinfected cohort [32]. We
observed an intent to treat SVR rate of 100% (95% CI:
80.2–100%) and 100% (95% CI: 74.9–100%) in patients
treated with SOF/LDV and 2D/3D, respectively. Two
patients died during therapy from a non-treatment-
related cause and were excluded from the analysis.
Additionally, several studies in HCV monoinfected pa-
tients with HCV-GT1 achieved equally high SVR rates
of ≥90% [33–36]; however, only 75% of genotype 3
patients were cured [34]. Our particularly high SVR
rate of 100% among patients with HCV-GT3 might




















be explained by the low proportion of patients with
cirrhosis and longer treatment durations.
Notably, since RBV reduces quality of life by in-
ducing anemia [37] we abstained from prescribing
RBV. A recent review on anti-HCV therapy in patients
with cirrhosis concluded that RBV confers no addi-
tional benefit in most patients as it only marginally
increases SVR rates at the cost of increased adverse
events [38]. Interestingly, 3 (14.3%) and 4 (26.7%) pa-
tients had detectable HCV-RNA at the end of treat-
ment in the SOF/LDV and 2D/3D group, respectively.
In all but one case, HCV-RNA was below the lower
limit of quantification. All HIV/HCV coinfected pa-
tients with low but detectable HCV-RNA at the end
of treatment achieved SVR. Low levels of viremia as-
sessed by the Abbott RealTime HCV assay at later
stages of treatment have previously been reported;
however, this was deemed insignificant as it does not
predict treatment failure [39]. Further studies are war-
ranted to investigate the ideal treatment duration for
every patient as it was done in the IFN era [40].
A change in antiretroviral therapy was necessary in
the majority of patients receiving 2D/3D, as coadmin-
istration with NNRTIs and PIs is not recommended
[23]; however, ART remained unchanged in two pa-
tients receiving atazanavir and rilpivirine. A recent
study demonstrated that morning administration of
atazanavir exhibits no clinically relevant DDIs [41].
Coadministration with rilpivirine was well-tolerated
in healthy volunteers; however, this combination
is not recommended as the observed elevations in
rilpivirine levels raise the risk for AEs [42]. We chose
a regimen consisting of 2 NRTIs and an II, most com-
monly a combination of tenofovir disoproxil fumarate,
emtricitabine and dolutegravir. Due to expected DDIs
or potential for DDIs, ART was changed in about
40% of patients receiving SOF/LDV. In retrospect, this
might not have been necessary in most cases [23].
Only a minority of patients had an undetectable
HIV-RNA throughout anti-HCV treatment. We ob-
served a high number of HIV-RNA blips, defined as
HIV-RNA <LLQ; however, there was no difference in
the amount of viremia and blips in the clinical visits
prior to and during DAA treatment. Since HIV-RNA
blips are a common finding in HIV-infected patients
[43], they should not be over-interpreted as an indi-
cator for clinically relevant DDIs. Nevertheless, we
cannot exclude that minor DDIs contributed to the
frequency of low levels of detectable HIV viremia de-
spite ART during concomitant anti-HCV regimens.
A recent publication by Sulkowski raised the ques-
tion on whether HIV/HCV coinfected patients should
still be considered a special population in the era of
second generation DAAs, since SVR rates are simi-
lar to HCV monoinfected patients. Notably, he con-
cluded that the term is still warranted as this popu-
lation faces specific challenges including reinfection,
frequent drug interactions and the unanswered ques-
tion of shortened treatment durations [44]. While the
term ‘hard to cure’ is not justified anymore, we agree
that treating HIV/HCV coinfected patients in special-
ized centres is still a necessity to address these clinical
challenges.
Similar to previous studies [27, 28] we observed
a rapid decline in liver stiffness which is unlikely to
be explained by fibrosis regression due to the short
time frame. The exact nature of how HCV eradication
reduces liver stiffness remains unknown, yet possible
mechanisms were discussed in a previous study [28].
The observed improvements are not limited to liver
stiffness but also include effects on portal pressure.
Previous studies observed a significant reduction of
portal hypertension after SVR to IFN-based [45] and
IFN-free therapies [46, 47].
The European Association for the Study of the
Liver (EASL) recommends treatment of HIV/HCV
coinfected patients regardless of degree of fibrosis
especially in those at risk of transmitting HCV [9].
Historically, in Austria the majority of HIV/HCV coin-
fected patients remained untreated [10]. With the
approval of second generation DAAs the reason of
under-treatment has shifted from medical contraindi-
cations and patient refusal to an economic dilemma.
Although treatment of patients with mild fibrosis but
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at high transmission risk is cost-effective [48], the
Austrian health insurance still employs strict criteria
for reimbursement to stick to the budget. Among
163 HIV/HCV coinfected patients who were referred
to the HIV & Liver Outpatient Clinic at the Medical
University of Vienna for evaluation of antiviral ther-
apy, 26 viremic HIV/HCV coinfected patients are now
‘waiting’ until liver disease progresses to fibrosis stage
F2 in order to become eligible for reimbursement of
IFN-free DAA therapy.
In summary, we achieved excellent SVR rates of
100% in a real-life cohort of HIV/HCV coinfected pa-
tients treated with SOF/LDV and 2D/3D. The ART was
changed prior to 2D/3D and SOF/LDV treatment in
a significant proportion of patients in order to avoid
expected DDIs. The HIV-RNA blips during DAA treat-
ment are common but should not be over-interpreted
as clinically significant DDIs. The HIV/HCV coin-
fected patients still represent a special population as
DDIs, as well as the prevention and management of
reinfections requires treatment at specialized centers.
Despite excellent SVR rates in clinical practice and
the EASL recommendation to prioritize treatment for
HIV/HCV coinfected patients regardless of fibrosis,
this is not yet the case in Austria. Thus, a large number
of patients at our outpatient clinic remain untreated
even though highly effective IFN-free DAA treatments
are available.
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